Burden of HIV Increasing Among Women
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
Women represented 8% of all AIDS diagnoses in the U.S. in 1985. By 2004, that percentage had risen to 27%.
Racial Disparities Among Women
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
The rate of HIV incidence among black women declined almost 7% from 2001 through 2004. However, the rate is still 21 times higher for black . . .
New Estimate of HIV/AIDS Epidemic in China
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
A new report, jointly released by the Chinese government, WHO, and UNAIDS, suggests that the number of HIV-infected people in China might be lower than . . .
Package Insert Updated for Atazanavir
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
The FDA has approved a new package insert for atazanavir that includes new data on in vitro inhibition as well as information on the coadministration . . .
50 Countries to Benefit from Lower Prices on HIV Tests and Treatment
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
The Clinton Foundation recently negotiated with several small manufacturers to lower the prices for rapid HIV tests and antiretrovirals in 50 developing countries. The reduced . . .
Pediatric HIV Treatment Guidelines Revised
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
Pediatric HIV treatment guidelines from DHHS/IDSA were recently updated to include information on tipranavir and on new formulations of FTC and lopinavir/ritonavir. The full text . . .
The Global HIV Epidemic
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
More than 40 million people in the world are living with HIV, including 4.9 million who were newly infected in 2005.
New Language for Latex Condom Labels?
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
The FDA recently proposed adding the following language to all latex condom labels: “Condoms greatly reduce, but do not eliminate, the risk of HIV transmission.” . . .
More Trials of CCR5 Antagonists Are Halted
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
On October 25, 2005, GlaxoSmithKline (GSK) announced that it has halted all trials of the CCR5 antagonist aplaviroc. Phase IIb trials in treatment-naive patients had . . .
Tablet Formulation of Kaletra Approved
HIV/AIDS Clinical Care AIDS Watch
Subscription Required
The FDA approved a new tablet formulation of lopinavir/ritonavir (200/50 mg) that offers several advantages over the current soft-gel capsule (133/33 mg) formulation:
